Keros Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KROS research report →
Companywww.kerostx.com
Keros Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis.
- CEO
- Jasbir S. Seehra
- IPO
- 2020
- Employees
- 163
- HQ
- Lexington, MA, US
Price Chart
Valuation
- Market Cap
- $351.34M
- P/E
- -4.80
- P/S
- 10.59
- P/B
- 1.43
- EV/EBITDA
- -0.90
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 96.48%
- Op Margin
- -332.55%
- Net Margin
- -256.60%
- ROE
- -17.04%
- ROIC
- -34.46%
Growth & Income
- Revenue
- $244.06M · 6774.96%
- Net Income
- $87.01M · 146.44%
- EPS
- $2.34 · 146.80%
- Op Income
- $70.62M
- FCF YoY
- 165.08%
Performance & Tape
- 52W High
- $22.55
- 52W Low
- $9.79
- 50D MA
- $11.36
- 200D MA
- $15.37
- Beta
- 0.95
- Avg Volume
- 432.01K
Get TickerSpark's AI analysis on KROS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | BIENAIME JEAN JACQUES | buy | 1,000 |
| Apr 15, 26 | BIENAIME JEAN JACQUES | buy | 1,000 |
| Apr 2, 26 | Seehra Jasbir | other | 55,000 |
| Apr 2, 26 | Seehra Jasbir | other | 55,000 |
| Feb 24, 26 | Cho Esther | other | 80,000 |
| Mar 9, 26 | Newton Charles W. | other | 14,788 |
| Mar 9, 26 | Newton Charles W. | other | 13,215 |
| Mar 9, 26 | Newton Charles W. | other | 0 |
| Mar 9, 26 | BIENAIME JEAN JACQUES | buy | 2,000 |
| Feb 24, 26 | Seehra Jasbir | other | 217,000 |
Our KROS Coverage
We haven't published any research on KROS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KROS Report →